Microba funds a sharper reset as GI Navigator launches and merger plans progress

• $2.025 million placement at $0.04 a share, with the second tranche conditional on approvals
• Cash and equivalents of $3.87 million after a $3.80 million quarterly operating outflow
• Core testing revenue rose 31% to $2.57 million, led by a 44% increase in Australian Microbiome Explorer tests
• Annualised cash operating costs reduced by more than 20%, with a further $3 million reduction planned